+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?

ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?

Mini Reviews in Medicinal Chemistry 11(12): 1082-1092

Although the clear mechanism of T2DM is still to be elucidated, it has been well established that reactive oxygen species (ROS) derived from multiple sources plays a causal role in multiple types of insulin resistance and contributes to β-cell dysfunction thus enhances the development and progression of T2DM. What is incomprehensible is that the detrimental ROS also plays a substantial role in the normal insulin signal transduction and glucose-stimulated insulin secretion (GSIS) in β-cell, which forces us to re-recognize the role of ROS under physiological and pathological conditions in a more broad way. Redox homeostasis is tightly controlled by the transcriptional factor nuclear factor erythroid 2-related factor 2 (Nrf2), whose abnormality is believed to be related with diabetes. Accumulating evidences suggest that there are important cross-talks between Nrf2 and PPARγ, PGC1α, PI3K/Akt on regulating antioxidant enzymes and the development of diabetes. Therefore, these evidences indicate that Nrf2 may be a critical element in taking survival and death decisions when cells are exposed to an oxidant environment. In conclusion, enhancing GSIS and insulin sensitivity through the regulation of Nrf2 levels is a potential avenue for developing new therapeutics. Nrf2 may become a promising target for the treatment of T2DM.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 055338278

Download citation: RISBibTeXText

PMID: 21861804

Related references

Ros Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?. Mini-Reviews in Medicinal Chemistry 11(12): 1082-1092, 2011

New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Translational Research 155(5): 211-216, 2010

Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword?. Drugs and Aging 8(3): 183-192, 1996

Infection and type 1 diabetes mellitus - a two edged sword?. Autoimmunity Reviews 8(8): 682-686, 2009

A double-edged sword against type 1 diabetes. New England Journal of Medicine 372(8): 778-780, 2015

Nrf2 in cancers: A double-edged sword. Cancer Medicine 8(5): 2252-2267, 2019

Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease. Mediators of Inflammation 2016: 8254797, 2016

Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential. Journal of Internal Medicine 268(5): 419-431, 2010

The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Molecular Cell 21(6): 732-734, 2006

GSK-3β, a double-edged sword in Nrf2 regulation: Implications for neurological dysfunction and disease. F1000research 7: 1043, 2018

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics 9(3): 661-675, 2019

Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 89: 34-44, 2017

Autophagy: a two-edged sword in diabetes mellitus. Biochemical Journal 456(3): E1-E3, 2013

Heat shock protein 90 inhibition: A potential double- or triple-edged sword in the treatment of mucous membrane pemphigoid. Medical Hypotheses 85(4): 412-414, 2015

Blue light acts as a double-edged sword in regulating sexual development of Hypocrea jecorina (Trichoderma reesei). Plos one 7(9): E44969, 2012